小脑
泛素蛋白连接酶类
DNA连接酶
化学
蛋白质降解
泛素连接酶
计算生物学
泛素
细胞生物学
蛋白酶体
生物
生物化学
酶
基因
作者
Joel W. Thompson,Thomas Clayton,Gody Khambatta,Leslie A. Bateman,Christopher W. Carroll,Philip P. Chamberlain,Mary E. Matyskiela
标识
DOI:10.1007/978-1-0716-1665-9_15
摘要
Targeted protein degradation is garnering increased attention as a therapeutic modality due in part to its promise of modulating targets previously considered undruggable. Cereblon E3 Ligase Modulating Drugs (CELMoDs) are one of the most well-characterized therapeutics employing this modality. CELMoDs hijack Cereblon E3 ligase activity causing neosubstrates to be ubiquitinated and degraded in the proteasome. Here, we describe a suite of assays-cellular substrate degradation, confirmation of CELMoD mechanism of action, in vitro ubiquitination, and Cereblon binding-that can be used to characterize CELMoD-mediated degradation of Cereblon neosubstrates. While the assays presented herein can be run independently, when combined they provide a strong platform to support the discovery and optimization of CELMoDs and fuel validation of targets degraded by this drug modality.
科研通智能强力驱动
Strongly Powered by AbleSci AI